A novel tumor-associated macrophage risk signature predicts prognosis and immunotherapy response in lung adenocarcinoma.

ABSTRACT:

Objective

To systematically characterize tumor-associated macrophage (TAM) subsets in lung adenocarcinoma (LUAD) and establish a TAM-based prognostic risk signature for LUAD patients.

Methods

Single-cell RNA sequencing (scRNA-seq) and bulk transcriptomic data were integrated to identify TAM subsets linked to LUAD prognosis. Prognostic genes were screened using univariate Cox regression, refined via Least Absolute Shrinkage and Selection Operator (LASSO) regression, and used to construct a 10-gene risk signature. The signature's performance was validated in independent cohorts through receiver operating characteristic curves, Kaplan-Meier survival analysis, and a nomogram. Its predictive ability for immune checkpoint inhibitor (ICI) therapy response was assessed in the IMvigo

SUBMITTER: Zhu Y 

PROVIDER: S-EPMC11982730 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature